No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

AIMS: Statins have modest adverse effects on glycaemic control. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers low-density lipoprotein cholesterol. This study assessed the effects of alirocumab on new-onset diabetes and pre-diabetes incidence in individuals without dia...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur Heart J
Päätekijät: Colhoun, Helen M., Ginsberg, Henry N., Robinson, Jennifer G., Leiter, Lawrence A., Müller-Wieland, Dirk, Henry, Robert R., Cariou, Bertrand, Baccara-Dinet, Marie T., Pordy, Robert, Merlet, Laurence, Eckel, Robert H.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2016
Aiheet:
Clinical Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081037/
https://ncbi.nlm.nih.gov/pubmed/27460890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehw292
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia